Key facts
- PURPOSE 5 compared twice-yearly injectable lenacapavir with daily oral F/TDF PrEP in the UK and France over 52 weeks.
- 85.6% of people on lenacapavir stayed persistent on PrEP, compared with 46.3% on daily tablets.
- There were no HIV acquisitions in the lenacapavir group and one in the daily-tablet group.
What happened
New results from the PURPOSE 5 study, presented at HIV Glasgow 2026, show that people starting HIV pre-exposure prophylaxis (PrEP) with a twice-yearly lenacapavir injection were almost twice as likely to stay on effective prevention for a full year as those starting daily tablets of emtricitabine/tenofovir disoproxil fumarate (F/TDF). Participants in the UK and France who were not already using PrEP were randomly assigned in a 2:1 ratio to the injection or to daily tablets.
After 52 weeks, 85.6% of participants in the lenacapavir group remained persistent, compared with 46.3% in the F/TDF group. Persistence for tablets was confirmed with blood tests showing at least four doses a week. No HIV infections occurred with lenacapavir; one occurred with tablets, in a person whose drug levels showed fewer than two doses a week. Serious adverse events were uncommon in both groups (3.9% and 3.4%) and none were judged related to treatment.
Why it matters
PrEP only works when people keep using it. Missing daily tablets is one of the main reasons prevention fails in real life. A long-acting option given twice a year removes the need to remember a pill every day and may be more discreet. Earlier trials (PURPOSE 1 and 2) had already shown very high protection with lenacapavir; this study adds evidence that people also stay on it far more consistently.
Context
The data come from the manufacturer and from a Phase 2 study, and persistence was measured differently for injections and tablets. Access is another question: an FDA tentative approval of a low-cost generic for lower-income countries was announced earlier this month, but availability and price still vary widely between countries.
What it means for clinicians and students
- Clinicians: when discussing PrEP, offer the full range of options, including long-acting injections where available, and plan follow-up visits for testing before each dose.
- Dental and surgical teams: PrEP use is part of a patient’s medication history; ask about it respectfully and keep it confidential.
- Students: a good example of the difference between efficacy in trials and effectiveness in real life, where adherence drives results.















